Economic Burden of Hepatitis C Virus Infection in Different Stages of Disease: A Report From Southern Iran
- PMID: 27257424
- PMCID: PMC4887962
- DOI: 10.5812/hepatmon.32654
Economic Burden of Hepatitis C Virus Infection in Different Stages of Disease: A Report From Southern Iran
Abstract
Background: Hepatitis C virus (HCV) infection is a major blood-borne infection which imposes high economic cost on the patients.
Objectives: The current study aimed to evaluate the total annual cost due to chronic HCV related diseases imposed on each patient and their family in Southern Iran.
Patients and methods: Economic burden of chronic hepatitis C-related liver diseases (chronic hepatitis C, cirrhosis and hepatocellular carcinoma) were examined. The current retrospective study evaluated 200 Iranian patients for their socioeconomic status, utilization (direct and indirect costs) and treatment costs and work days lost due to illness by a structured questionnaire in 2015. Costs of hospital admissions were extracted from databases of Nemazee hospital, Shiraz, Iran. The outpatient expenditure per patient was measured through the rate of outpatient visits and average cost per visit reported by the patients; while the inpatient costs were calculated through annual rate of hospital admissions and average expenditure. Self-medication and direct non-medical costs were also reported. The human capital approach was used to measure the work loss cost.
Results: The total annual cost per patient for chronic hepatitis C, cirrhosis and hepatocellular carcinoma (HCC) based on purchasing power parity (PPP) were USD 1625.50, USD 6117.2, and USD 11047.2 in 2015, respectively.
Conclusions: Chronic hepatitis C-related liver diseases impose a substantial economic burden on patients, families and the society. The current study provides useful information on cost of treatment and work loss for different disease states, which can be further used in cost-effectiveness evaluations.
Keywords: Cirrhosis; Cost; Economics; Hepatitis C; Hepatocellular Carcinoma.
Figures
Similar articles
-
Economic burden of hepatitis B virus infection in different stages of disease; a report from southern iran.Middle East J Dig Dis. 2014 Jul;6(3):156-61. Middle East J Dig Dis. 2014. PMID: 25093064 Free PMC article.
-
Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China.Value Health. 2009 Nov-Dec;12 Suppl 3:S89-92. doi: 10.1111/j.1524-4733.2009.00636.x. Value Health. 2009. PMID: 20586991
-
[Survey of economic burden of hepatitis B-related diseases in 12 areas in China].Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Jul 10;38(7):868-876. doi: 10.3760/cma.j.issn.0254-6450.2017.07.005. Zhonghua Liu Xing Bing Xue Za Zhi. 2017. PMID: 28738457 Chinese.
-
Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas.J Med Econ. 2012;15(5):887-96. doi: 10.3111/13696998.2012.681332. Epub 2012 May 24. J Med Econ. 2012. PMID: 22458755 Review.
-
Hepatitis C virus: A time for decisions. Who should be treated and when?World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):33-40. doi: 10.4292/wjgpt.v7.i1.33. World J Gastrointest Pharmacol Ther. 2016. PMID: 26855810 Free PMC article. Review.
Cited by
-
Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS).BMC Res Notes. 2021 Feb 10;14(1):59. doi: 10.1186/s13104-021-05474-2. BMC Res Notes. 2021. PMID: 33568187 Free PMC article.
-
Prevalence of hepatitis E virus in thalassemia patients with hepatitis C in Tehran, Iran.Iran J Microbiol. 2019 Dec;11(6):535-540. Iran J Microbiol. 2019. PMID: 32148686 Free PMC article.
-
Impact of newer direct-acting antiviral drugs based on quality-adjusted life years: A prospective pharmacoeconomic study in hepatitis C patients.Perspect Clin Res. 2021 Apr-Jun;12(2):76-82. doi: 10.4103/picr.PICR_123_19. Epub 2020 May 7. Perspect Clin Res. 2021. PMID: 34012903 Free PMC article.
-
Prevalence of HBV, HCV, and HIV Infections among Patients Undergoing Hemodialysis in Fasa, Iran: A Six-Year Follow-up Study.Middle East J Dig Dis. 2022 Jul;14(3):317-322. doi: 10.34172/mejdd.2022.289. Epub 2022 Jul 30. Middle East J Dig Dis. 2022. PMID: 36619273 Free PMC article.
-
Economic Burden of Inflammatory Bowel Disease in Shiraz, Iran.Arch Iran Med. 2023 Jan 1;26(1):23-28. doi: 10.34172/aim.2023.04. Arch Iran Med. 2023. PMID: 37543918 Free PMC article.
References
-
- Alavian SM. We Need a New National Approach to Control Hepatitis C: It is Becoming too Late. Hepat Mon. 2008;8(3):165–9.
-
- Malekzadeh R, Khatibian M, Rezvan H. Viral hepatitis in the world and Iran; epidemiology, diagnosis, prevention and treatment. Sci J Med Council Islam Republic Iran. 1997;15:183–200.
LinkOut - more resources
Full Text Sources
Other Literature Sources